All In Biotech

NDA 202293 · Astrazeneca Ab

Farxiga

Dapagliflozin · Oral

NovelBreakthrough therapy

Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Jan 8, 2014

Approved uses

9

Original approval plus efficacy supplements

Registered trials

659

182 Phase 3, 102 recruiting

FAERS reports

60,513

46,653 serious, 10,454 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 18, 2026.

FARXIGA (dapagliflozin) is indicated: To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors. As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Limitations of Use FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] . FARXIGA is not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2 . FARXIGA is likely to be ineffective in this setting based upon its mechanism of action. FARXIGA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. FARXIGA is not expected to be effective in these populations. FARXIGA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated: To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. (1) To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. (1) To reduce the risk of hospitalization for...

Mechanism: Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and thereby promotes urinary glucose excretion. Dapagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, lowering both pre- and afterload of the heart and downregulation of...

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • FARXIGA · DAPAGLIFLOZIN 10MG · TABLET, ORAL · Prescription · TE AB
  • FARXIGA · DAPAGLIFLOZIN 5MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Dapagliflozin" as an intervention, any sponsor and status, largest first.

All 659 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death8,511
  • fatigue2,672
  • nausea2,619
  • diarrhoea2,478
  • dizziness2,464
  • dyspnoea2,308
  • off label use2,128
  • weight decreased2,048
  • acute kidney injury2,047
  • blood glucose increased2,010
  • vomiting1,936
  • headache1,789

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
200910
20109
20117
201211
20139
2014860
20151,530
20161,255
20171,288
20181,574
20191,468
20201,724
20212,889
20225,131
20238,710
202411,383
202512,936
20269,718

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Farxiga (Dapagliflozin Propanediol)

2024 spending

$5.29B

Beneficiaries

1,269,216

5,634,650 claims

Per beneficiary

$4,168

$18.31 per unit

View as table
YearSpending
2020$736,787,564
2021$1,421,505,274
2022$2,584,621,150
2023$4,342,182,307
2024$5,290,548,963

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 913 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.